We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Sam9.0
SAMe Research
Mostly mechanism / observationalModerate safety
14 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most SAMe studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2004–2026 with a typical study size of 656 participants.
Based on 14 studies · 3 meta-analyses · 5 RCTs · 4,952 total participants
Confidence
High
What the studies found
0helped2unclear· 12 more without graded effect data
By outcome
Depression & moodSignificant improvement in depressive symptoms · 2-6 weeks
Mostly mechanism / observational11 studies
Therapeutic & clinical
Mostly mechanism / observational5 studies
Joint pain & arthritisComparable to NSAIDs for osteoarthritis pain in clinical trials · 4-8 weeks
Too few graded studies2 studies
Cognitive function
Too few graded studies2 studies
Liver health
Too few graded studies1 study
Neuroprotection & brain aging
Too few graded studies1 study
Heart & blood pressure
Too few graded studies1 study
Safety profile
Too few graded studies1 study
By the numbers
Pulled from 9 studies with measurable effects
People studied
4,952
typical study: 656 people
Strongest designs
8
3 pooled, 5 randomised
Showed benefit
0%
0/2 studies
How long studies ran
1–3 months
1
Populations Studied
Adults with mild depression1
Participants receiving SAM supplementation1
Patients with depression1
Patients with liver diseases1
Active research area
10 studies in the last 5 years · Latest meta-analysis: 2025
200420152026
1Depression response ratesMeta-Analysisn=1,049 · large study2025
This review demonstrates that certain supplements, such as eicosapentaenoic acids and Rhodiola rosea, are therapeutic options for mild depression.
Urata M et al. · Neuropsychopharmacology reports (2025)
No clear effect
← WorseNo effectBetter →
A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88).
Eicosapentaenoic acid and Rhodiola rosea demonstrated significant improvements in depressive symptoms compared to placebo.
Conversely, S-adenosylmethionine did not produce significant improvements relative to placebo.
5Pain reductionMeta-AnalysisCited 40×n=656 · large study2009
The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality.
Rutjes AW et al. · The Cochrane database of systematic reviews (2009)
No clear effect
← WorseNo effectBetter →
For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I(2) = 0).
For function, the analysis suggested a SMD of 0.02 (95% CI -0.68 to 0.71) with a moderate degree of between-trial heterogeneity (I2 = 54%).
The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality.
Appropriate levels of these micronutrients should then be monitored at all stages of development for a healthier brain.
Bekdash RA · International journal of molecular sciences (2023)
Studies in human and animal models have indicated the importance of the optimal levels of methyl donors on brain health and behavior across the lifespan.
Imbalances in the levels of these micronutrients during critical periods of brain development have been linked to epigenetic alterations in the expression of genes that regulate normal brain function.
We present studies that support the link between imbalances in the levels of methyl donors, epigenetic alterations, and stress-related disorders.
In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms.
Dording CM et al. · European psychiatry : the journal of the Association of European Psychiatrists (2012)
In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms.
These findings are preliminary, and warrant replication.
CLINICAL TRIALS.GOV IDENTIFIER: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/NCT00093847.
This systematic-review examined the effects of SAMe.
Karimi K et al. · Amino acids (2026)
Starvation suppresses mTORC1 activity, leading to reduced ribosome biogenesis and translation while promoting autophagy to meet cellular energy demands.
We discuss the adaptive mechanisms by which reduced levels of acetyl-CoA, amino acids, EP300, glucose, insulin, and S-adenosylmethionine inhibit mTORC1 and simultaneously induce autophagy.
Additionally, we describe the adaptive role that glucagon, Sestrin2, and urea play to inhibit mTORC1 and how eIF5A, glucagon, spermidine, and TFEB induce autophagy.
There is evidence of a potential benefit of SAMe as an intervention to help with symptoms across the range of post-concussive sequelae and syndromes commonly seen in military mTBI.
Schieffler DA et al. · Military medicine (2022)
There is evidence of a potential benefit of SAMe as an intervention to help with symptoms across the range of post-concussive sequelae and syndromes commonly seen in military mTBI.
Since the discovery of SAMe in 1952, this pleiotropic molecule has shown the significance of its involvement in several metabolic cascades in such disparate systems as epigenetics, bioenergetics, DNA methylation, neurotransmitter systems, and potential usefulness in military TBI.
Significant limitations include disparate presentations seen in patients with mild TBI, those with post-concussive syndrome, as well as those with comorbid depression and posttraumatic stress disorder.
This is the first demonstration of a nutritional product's effectiveness in decreasing plasma levels of SAH in otherwise healthy individuals with elevated SAH and normal Hcy.
Pohl F et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD (2025)
The test product significantly lowered plasma SAH levels by approximately 12% and increased S-Adenosylmethionine (SAM): SAH ratio by approximately 26% after 12 weeks of supplementation compared to baseline.
This is the first demonstration of a nutritional product's effectiveness in decreasing plasma levels of SAH in otherwise healthy individuals with elevated SAH and normal Hcy.
Hence, this test product offers a unique opportunity for investigating the impact of lowering plasma SAH on the risk of developing CVD and other diseases.